IPO Databook: Suzhou Genhouse Bio (HK) - Aug 2026

128 Views09 Aug 2026 10:22

SUMMARY

Suzhou Genhouse Bio Co., Ltd., founded in May 2014, develops innovative oncology drug candidates, focusing on RAS signaling pathways and synthetic lethality mechanisms. It seeks a primary HKEX Main Board.
Suzhou Genhouse Bio owns 38 granted patents and 120 patent applications, with GH21 being the second clinically advanced SHP2 inhibitor globally.
Revenue was RMB557,741 for five months ended May 31, 2026, while 2024 saw a RMB(151,775) loss.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream